Navigation Links
Immune Design Announces $18 Million Series A Financing
Date:6/23/2008

Company to Focus on Prophylactic and Therapeutic Vaccines for Infectious

Diseases

SEATTLE, June 23 /PRNewswire/ -- Immune Design, a new generation vaccine company built on emerging understanding of the human immune system, today announced the closing of an $18 million Series A financing. The current round was co-led by Alta Partners, The Column Group and Versant Ventures. The Column Group initially incubated the Company.

"We are pleased and fortunate to have such an outstanding syndicate of investors joining a world class team of experienced founders and scientific leaders at Immune Design," said Steven Reed, Ph.D., Chief Executive Officer. "While vaccines and immunotherapeutics represent a growing market that is receiving increased interest from pharmaceutical companies, true innovation in the field has been stagnant. We are working to leverage breakthrough technologies toward developing new and better approaches to this area."

Most current vaccines and immunization protocols rely on generic stimulation of the immune system -- a limited and inefficient method. Immune Design is addressing these limitations with improved adjuvants and novel technologies targeting and controlling dendritic cells, which have recently been shown to orchestrate how effectively the immune system mounts an effective response. This approach could create an entirely new generation of prophylactic and therapeutic vaccines for infectious diseases and extend the coverage of current vaccines. The company expects to be in the clinic within 12 months with vaccines using its best in class molecular adjuvants, which will soon be followed by novel vaccines using the dendritic cell directed platform.

The Company's founders include Dr. David Baltimore, Nobel Laureate, President Emeritus of Cal Tech and one of the world's most prominent immunologists; Dr. Steven Reed, founder of the Infectious Disease Research Institute (IDRI), founder and former Chief Scientific Officer of Corixa and an authority in the areas of infectious diseases and molecular adjuvants; and Dr. Larry Corey, Chief of Infectious Diseases at the Fred Hutchison Cancer Research Center and a world expert in HIV and Herpes virology as well as a leading vaccinologist. Additional founding scientists, Dr. Lili Yang of Cal Tech and Dr. Pin Wang of University of Southern California bring their new vaccine technologies to Immune Design.

"By targeting dendritic cells, we hope to both improve the response to current antigens and tailor the cellular and hormonal response to address new disease areas," said Dr. Baltimore. "In addition, our novel adjuvant program is generating highly immunogenic adjuvants with improved reactogenic properties which will broaden protection across patient populations and minimize the amount of antigen required." Dr. Ed Penhoet, Partner at Alta Partners and former CEO of Chiron Corporation will serve as Board Chairman. Other Board members include Dr. Richard Klausner, Partner in The Column Group, former Director of the National Cancer Institute and former Executive Director of Global Health at the Bill and Melinda Gates Foundation, Dr. Baltimore and Dr. Brian Atwood, Partner at Versant Ventures.

"Vaccines generated over $16 billion dollars in sales in 2007. Influenza vaccines alone are predicted to reach over $4 billion in sales by 2012," said Dr. Penhoet. "At Immune Design, we see a unique opportunity to develop a platform technology that could be used to efficiently generate multiple vaccines to address a wide range of infectious diseases."

Dr. Larry Corey will chair an illustrious Scientific Advisory Board that includes Dr. Ralph Steinman, Henry G. Kunkel Professor and Senior Physician at Rockefeller University and the discoverer of dendritic cells; Dr. Inder Verma, professor in the Laboratory of Genetics and American Cancer Society Professor of Molecular Biology at the Salk Institute and a leading virologist; Dr. Rafi Ahmed, Emory Vaccine Center Director, Professor of Microbiology and Immunology in the Emory University School of Medicine and a leading immunologist; Dr. Martin Friede, a vaccine specialist with the World Heath Organization and a recognized expert on molecular adjuvants and Dr. Bruce Beutler, Professor and Chairman of the Department of Genetics at the Scripps Research Institute, whose research has focused on infectious disease and immunity.

Immune Design is headquartered in Seattle, Washington.

About Immune Design

Immune Design is a new generation vaccine company built on emerging understanding of the human immune system. Immune Design has identified improved adjuvants and novel technologies targeting and controlling dendritic cells, which have recently been shown to orchestrate how effectively the immune system mounts an effective response. Unlike most vaccines and immunization protocols that rely on more limited and less efficient generic stimulation of the immune system, Immune Design's approach could create an entirely new generation of prophylactic and therapeutic vaccines for infectious diseases and extend the coverage of current vaccines. http://www.immunedesign.com

About Alta Partners

Additional information regarding Alta Partners can be found at http://www.altapartners.com

About The Column Group

Additional information regarding TCG can be found at http://www.thecolumngroup.net

About Versant Ventures

Additional information regarding Versant Ventures can be found at http://www.versantventures.com


'/>"/>
SOURCE Immune Design
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. Immune deficiency linked to a type of eye cancer
3. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
4. Melanoma drug revs immune cells but cancer cells ignore it
5. Study identifies key player in the bodys immune response to chronic stress
6. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
7. UVA researchers find important clue to immune infertility
8. M.D. Anderson-led team reports possible key to autoimmune disease
9. Their immune cells, fighting your cancer
10. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
11. Occupational exposures may be linked to death from autoimmune disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology: